Fed. Circ. Rules Glenmark Infringed Bayer's Finacea Patent
The Federal Circuit on Monday affirmed a lower court's ruling that Glenmark infringed a Bayer Healthcare patent for the rosacea treatment Finacea, keeping Glenmark's planned generic version off the market until the...To view the full article, register now.
Already a subscriber? Click here to view full article